Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Insider Gina Mazzariello Sells 10,455 Shares

Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) insider Gina Mazzariello sold 10,455 shares of the stock in a transaction on Wednesday, May 15th. The stock was sold at an average price of $1.88, for a total value of $19,655.40. Following the sale, the insider now directly owns 151,477 shares of the company’s stock, valued at $284,776.76. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

Gina Mazzariello also recently made the following trade(s):

• On Tuesday, March 5th, Gina Mazzariello sold 1,540 shares of Amylyx Pharmaceuticals stock. The stock was sold at an average price of $18.73, for a total value of $28,844.20.
• On Friday, February 23rd, Gina Mazzariello sold 2,838 shares of Amylyx Pharmaceuticals stock. The stock was sold at an average price of $18.76, for a total value of $53,240.88.

Amylyx Pharmaceuticals Price Performance

NASDAQ:AMLX traded up $0.02 during mid-day trading on Friday, reaching $1.85. The company’s stock had a trading volume of 555,841 shares, compared to its average volume of 2,640,296. The company’s fifty day simple moving average is $2.40 and its two-hundred day simple moving average is $10.87. Amylyx Pharmaceuticals, Inc. has a twelve month low of $1.70 and a twelve month high of $27.99. The stock has a market cap of $125.82 million, a P/E ratio of -1.71 and a beta of -0.68.

Amylyx Pharmaceuticals (NASDAQ:AMLX) last issued its quarterly earnings results on Friday, May 10th. The company reported ($0.46) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.24 by ($0.70). Amylyx Pharmaceuticals had a positive return on equity of 4.14% and a negative net margin of 17.86%. The business had revenue of $88.64 million during the quarter, compared to analyst estimates of $113.26 million. During the same period in the previous year, the business posted $0.02 earnings per share. Sell-side analysts expect that Amylyx Pharmaceuticals, Inc. will post -0.93 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on the company. Evercore ISI reaffirmed an “in-line” rating on shares of Amylyx Pharmaceuticals in a report on Friday, March 8th. HC Wainwright restated a “buy” rating and issued a $8.00 price target on shares of Amylyx Pharmaceuticals in a research report on Friday, May 10th. The Goldman Sachs Group restated a “neutral” rating on shares of Amylyx Pharmaceuticals in a research report on Friday, March 8th. SVB Leerink cut Amylyx Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research report on Monday, March 11th. Finally, Mizuho dropped their price objective on Amylyx Pharmaceuticals from $4.00 to $3.00 and set a “neutral” rating for the company in a research report on Tuesday. Six research analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $28.67.

Hedge Funds Weigh In On Amylyx Pharmaceuticals

Several hedge funds and other institutional investors have recently modified their holdings of the company. Price T Rowe Associates Inc. MD lifted its stake in shares of Amylyx Pharmaceuticals by 8.5% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 970,555 shares of the company’s stock valued at $2,757,000 after purchasing an additional 75,775 shares in the last quarter. Vanguard Group Inc. lifted its stake in shares of Amylyx Pharmaceuticals by 1.4% in the 1st quarter. Vanguard Group Inc. now owns 5,348,139 shares of the company’s stock valued at $15,189,000 after purchasing an additional 72,573 shares in the last quarter. Swiss National Bank lifted its stake in shares of Amylyx Pharmaceuticals by 8.7% in the 1st quarter. Swiss National Bank now owns 86,600 shares of the company’s stock valued at $246,000 after purchasing an additional 6,900 shares in the last quarter. Capstone Investment Advisors LLC lifted its stake in shares of Amylyx Pharmaceuticals by 300.4% in the 1st quarter. Capstone Investment Advisors LLC now owns 80,084 shares of the company’s stock valued at $227,000 after purchasing an additional 60,084 shares in the last quarter. Finally, Allspring Global Investments Holdings LLC lifted its stake in shares of Amylyx Pharmaceuticals by 52,575.9% in the 1st quarter. Allspring Global Investments Holdings LLC now owns 15,276 shares of the company’s stock valued at $43,000 after purchasing an additional 15,247 shares in the last quarter. 95.84% of the stock is owned by institutional investors and hedge funds.

About Amylyx Pharmaceuticals

Amylyx Pharmaceuticals, Inc, a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada.